Home
Live Updates
Phase 3 Trial of Pembrolizumab with Olaparib Did Not Meet Endpoints Among Individuals with NSCLC : vimarsana.com
Phase 3 Trial of Pembrolizumab with Olaparib Did Not Meet Endpoints Among Individuals with NSCLC
Pembrolizumab in combination with chemotherapy followed by maintenance olaparib did not meet its pre-specified statistical criteria of overall survival or progression free survival.
Related Keywords
,
Gregory Lubiniecki ,
Merck Sharp Dohme ,
Merck Research Laboratories ,
Pembrolizumab With Maintenance Olaparib ,
Maintenance Pemetrexed ,
Metastatic Nonsquamous Non Small Cell Lung Cancer ,
Merck Sharp ,
Provides Update ,
Plus Maintenance Lynparza ,
vimarsana.com © 2020. All Rights Reserved.